Great West Life Assurance Co. Can Has $36,000 Stock Position in STAAR Surgical (NASDAQ:STAA)

Great West Life Assurance Co. Can lowered its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 73.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 1,391 shares of the medical instruments supplier’s stock after selling 3,781 shares during the period. Great West Life Assurance Co. Can’s holdings in STAAR Surgical were worth $36,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of STAA. GSA Capital Partners LLP grew its position in STAAR Surgical by 3.0% during the 2nd quarter. GSA Capital Partners LLP now owns 16,720 shares of the medical instruments supplier’s stock worth $491,000 after acquiring an additional 481 shares during the last quarter. Panagora Asset Management Inc. grew its position in STAAR Surgical by 2.3% during the 2nd quarter. Panagora Asset Management Inc. now owns 25,582 shares of the medical instruments supplier’s stock worth $752,000 after acquiring an additional 565 shares during the last quarter. AdvisorNet Financial Inc grew its position in STAAR Surgical by 54.8% during the 2nd quarter. AdvisorNet Financial Inc now owns 1,742 shares of the medical instruments supplier’s stock worth $51,000 after acquiring an additional 617 shares during the last quarter. Advisor Group Inc. grew its position in STAAR Surgical by 4.3% during the 2nd quarter. Advisor Group Inc. now owns 22,817 shares of the medical instruments supplier’s stock worth $670,000 after acquiring an additional 937 shares during the last quarter. Finally, Royal Bank of Canada grew its position in STAAR Surgical by 483.3% during the 2nd quarter. Royal Bank of Canada now owns 1,190 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 986 shares during the last quarter. 90.74% of the stock is owned by institutional investors.

In other STAAR Surgical news, CTO Keith Holliday sold 2,100 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $35.00, for a total value of $73,500.00. Following the sale, the chief technology officer now owns 28,764 shares in the company, valued at approximately $1,006,740. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.30% of the company’s stock.

A number of equities research analysts recently weighed in on STAA shares. BidaskClub upgraded STAAR Surgical from a “strong sell” rating to a “sell” rating in a research report on Tuesday. Zacks Investment Research lowered STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, October 19th. Finally, ValuEngine upgraded STAAR Surgical from a “hold” rating to a “buy” rating in a research report on Friday, October 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $34.00.

NASDAQ STAA opened at $35.49 on Friday. The business’s 50-day moving average price is $28.55 and its two-hundred day moving average price is $28.91. STAAR Surgical has a 12 month low of $21.70 and a 12 month high of $49.84. The firm has a market capitalization of $1.60 billion, a PE ratio of 126.75 and a beta of 2.34. The company has a current ratio of 5.50, a quick ratio of 4.96 and a debt-to-equity ratio of 0.03.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.05 EPS for the quarter, meeting analysts’ consensus estimates of $0.05. STAAR Surgical had a return on equity of 13.84% and a net margin of 6.15%. The firm had revenue of $39.06 million for the quarter, compared to analyst estimates of $37.50 million. As a group, analysts forecast that STAAR Surgical will post 0.22 earnings per share for the current fiscal year.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Featured Article: Quick Ratio

Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAA).

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.